IONIQ Sciences, Inc.

IONIQ Sciences, Inc. is a public company based in Salt Lake City, Utah, founded in 2004. The company specializes in medical devices aimed at the early detection of multiple cancers, particularly lung and breast cancer. Its mission is to enhance cancer outcomes by offering modern, non-invasive screening solutions that identify cancer at its earliest and most treatable stages. The company's core technology, Electrical Impedance Analytics (EIA), allows for the collection of extensive electrical readings from the body to assess the likelihood of cancer presence. IONIQ Sciences' primary products include the ProLung Test™, a non-invasive lung cancer screening that has received FDA Breakthrough Device Designation, and a breast cancer test currently in feasibility studies. The company is also developing a comprehensive multi-cancer screening platform. With a focus on early detection, IONIQ Sciences aims to improve survivability and reduce healthcare costs for patients and providers.

• Employees 13
• Founded 2004
• Annual Revenue $5000000
• Total Funding $3300000